Dengue Vaccines Market is expected to reach a valuation of US$ 1 billion by 2031 | FMI Study

The global Dengue Vaccines Market is expected to grow at a staggering double-digit CAGR through 2031, surpassing US$ 1 billion during the forecast period, according to Future Market Insights (FMI), an ESOMAR-certified market research firm.

Growth is majorly underpinned by the rising incidence of dengue fever across endemic regions.

According to the World Health Organization, 70% of the total disease burden is prevalent across Asia, thereby encouraging prominent pharmaceutical giants to increase inroads across such countries as India, the Philippines and Japan.

Presently, the market appears highly consolidated, attributed to the existence of just one effective vaccine candidate- Sanofi Pasteur’s Dengvaxia®.

However, future pipeline projects by other prominent giants is likely to enhance the scope of the market.

Request a Sample Report with Table of Content (ToC) @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1763

For instance, since 2018, Sun Pharmaceuticals Ltd. is working on the DSV4 vaccine which is expected to provide protection against dengue infection to previously unaffected patients.

Likewise, since 2017, the Serum Institute of India has been developing the VIS513 monoclonal antibody which have exhibited positive outcomes in neutralizing the dengue virus in animal mode studies, with a breakthrough expected in 2021.

Key Takeaways from FMI’s Dengue Vaccines Market Study

• CYD-TDV (Dengvaxia) to retain its dominance in the global dengue vaccines market, alternative candidates are under investigation
• By end-user, governments are expected to pivot majority of dengue vaccines demand in forthcoming years
• Major pharmaceutical giants are concentrating on developing live attenuated dengue vaccines amid their perceived greater effectiveness
• US to experience escalating growth, amid ongoing clinical trials to develop more vaccine candidates
• Mexico is expected to emerge as an attractive destination for dengue vaccine manufacturers
• Rising health & hygiene initiatives to spur dengue vaccines development across India
• Brazil to pivot most of the Latin American dengue vaccine market, amid an extremely high prevalence rate

Speak to our Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-1763

Competitive Landscape

• Sanofi Pasteur Limited
• Takeda Pharmaceutical Company Limited
• Merck & Co. Inc.
• GlaxoSmithKline Plc.
• GeneOne Life Science Inc.
• Medigen Vaccine Biologics Corporation
• Panacea Biotec Limited
• Sun Pharmaceutical Industries Ltd
• Serum Institute of India Pvt. Ltd.
• Biological E Ltd.

Prominent players are looking to constantly introduce new vaccine candidates in order to remain afloat in the market. In 2020, Medigen Vaccine Biologics Corporation (MVC) completed the phase II study for the TetraVax-DV dengue vaccine in Taiwan, thereby establishing the safety and efficacy of the candidate. It subsequently initiated phase III of the study.

Likewise, in September 2020, Panacea Biotec Limited completed of its Phase I/II study of its novel, tetravalent recombinant chimeric Dengue candidate vaccine christened DengiAll.

After a single dose, over 80% of the participants exhibited more than a trivalent response and around 95% showed multivalent response.

To Buy this Report Visit @ https://www.futuremarketinsights.com/checkout/1763

Reasons to Buy the report

• We provide authentic and detailed an analysis on various market trends to enable businesses to make informed and beneficial decisions to attain competitive edge over key players.
• Our analysts provide detailed market segmentation along with meaningful insights and extensive reports that other companies fail to include.

• The report includes accurate analysis of the market and the current developing trends affecting the growth. FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. This ensures that the data collected is from highly reliable sources.

Key Segments Covered

Product

• CYD-TDV (Dengvaxia)

End-User

• Hospitals
• Government Institutes
• Non-governmental Organizations (NGOs)

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments based on Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs